Solana Beach, California — August 17, 2026
Artelo Biosciences, Inc. announced that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a U.S. patent application covering the intended commercial formulation of ART27.13, the company’s lead investigational drug currently being evaluated in two Phase 2 studies. The allowed patent claims cover compositions of ART27.13 dispersed in polyethylene glycol, including the formulation Artelo intends to use commercially. The company expects the resulting patent to provide protection for ART27.13 through 2041, strengthening the intellectual property position around the program as clinical development continues in cancer-related anorexia and glaucoma or ocular hypertension. The patent milestone adds further protection to a drug candidate being developed across multiple potential indications.
ART27.13 Gains Protection for Intended Commercial Formulation
The USPTO Notice of Allowance represents an important intellectual property milestone for ART27.13, particularly because the allowed claims cover the formulation intended for potential commercial use. Artelo is developing ART27.13 as a once-daily, orally administered investigational therapy designed to selectively target peripheral CB1 and CB2 cannabinoid receptors while limiting central nervous system exposure. The company believes this peripheral selectivity could enable metabolic effects while reducing toxicity associated with centrally acting cannabinoid therapies. The expected patent protection through 2041 could provide a longer-term intellectual property foundation for the program as Artelo advances clinical development and evaluates additional commercial opportunities. However, a Notice of Allowance is not the same as an issued patent, and the final patent protection will depend on completion of the remaining USPTO issuance process.
ART27.13 Advances in Two Phase 2 Studies
ART27.13 is currently being evaluated in two Phase 2 clinical programs, giving the new patent milestone relevance across multiple development opportunities. The CAReS Phase 2 study is evaluating ART27.13 as a supportive-care treatment for cancer-related anorexia and weight loss. According to Artelo, interim Phase 2 findings showed that patients receiving the highest dose demonstrated reversal of cancer-related anorexia, while participants receiving placebo continued to lose weight during the study. Earlier Phase 1 development also indicated that the drug was well tolerated and showed preliminary evidence of stabilizing or reversing weight loss. The second program, the investigator-led DREAM Phase 2 study, is evaluating ART27.13 in patients with glaucoma or ocular hypertension as a potential once-daily oral treatment intended to reduce intraocular pressure. Initial results from DREAM are anticipated in the fourth quarter of 2026.
Advertisement
Artelo Strengthens Long-Term Development Strategy
The patent development strengthens the broader ART27.13 development and commercialization strategy as Artelo evaluates the investigational drug across cancer supportive care and ophthalmology. The compound was initially developed by AstraZeneca and has previously been evaluated in seven clinical studies involving more than 280 participants. Artelo is now advancing the program through its own clinical development strategy, with CAReS and DREAM representing the current Phase 2 studies. The company is particularly targeting significant unmet needs, including cancer-related anorexia and weight loss, for which Artelo states there is currently no FDA-approved treatment specifically addressing the condition. If future clinical studies confirm meaningful efficacy and safety, the expected intellectual property protection could support development and potential commercialization across multiple indications. For now, however, ART27.13 remains investigational, and the patent milestone does not establish clinical efficacy or regulatory approval.
Source: Artelo Biosciences press relese
